Gemtuzumab for Relapsed Acute Myeloid Leukemia
Gemtuzumab ozogamicin, a monoclonal antibody bound to a cytotoxic antibiotic, has been approved by the FDA for treatment of patients with CD33-positive acute myeloid leukemia (AML) in first relapse who are more than 60 years old and may not be able to tolerate cytotoxic chemotherapy...
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Gemtuzumab for Relapsed Acute Myeloid Leukemia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1083
Article Code: 1083b
Date: July 24, 2000
Volume: 42
Pages: 67-68
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1083
Article Code: 1083b
Date: July 24, 2000
Volume: 42
Pages: 67-68
Add this downloadable, electronic article to your cart (U.S. English version only) Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.